Clinical Trials Using Trametinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trametinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 36
1 2 Next >

  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1196 locations

  • Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

    This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 54 locations

  • Dabrafenib, Trametinib, and Navitoclax in Treating Patients with BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    This phase I / II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that have spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). Dabrafenib, trametinib, and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 31 locations

  • Trametinib in Treating Patients with Epithelioid Hemangioendothelioma that is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

    This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot be removed by surgery (unresectable). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 24 locations

  • Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG

    The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.
    Location: 10 locations

  • Trametinib with or without Dabrafenib Mesylate in Treating Patients with BRAF, KRAS, or NRAS Gene Mutation and Recurrent Multiple Myeloma

    This phase II trial studies how well trametinib with or without dabrafenib mesylate works in treating patients with BRAF, KRAS, or NRAS gene mutation and multiple myeloma that has come back. Trametinib and dabrafenib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

    To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
    Location: 6 locations

  • A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

    The primary objective of this trial is to determine the maximum tolerated dose (MTD) and / or recommended Phase II dose (RP2D) of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated solid tumours. Secondary objectives are to evaluate the safety and tolerability of BI 1701963 as monotherapy and in combination with trametinib, to characterise pharmacokinetics and pharmacodynamics, and to evaluate first efficacy signals.
    Location: 3 locations

  • Pediatric Long-Term Follow-up and Rollover Study

    A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and / or trametinib.
    Location: 4 locations

  • Dabrafenib, Trametinib, and Spartalizumab in Treating Patients with BRAFV600E Mutant Metastatic Colorectal Cancer

    This phase II trial studies the side effects and how well dabrafenib, trametinib, and spartalizumab work in treating patients with BRAFV600E mutant colorectal cancer that has spread to other places in the body. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as spartalizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving dabrafenib, trametinib, and spartalizumab may work better in treating patients with BRAFV600E mutant colorectal cancer.
    Location: 3 locations

  • Pembrolizumab and Trametinib with or without Dabrafenib in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery

    This phase II trial studies how well pembrolizumab and trametinib with or without dabrafenib work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib with or without dabrafenib may work better in treating patients with melanoma.
    Location: 3 locations

  • Phenformin Hydrochloride, Dabrafenib, and Trametinib in Treating Patients with Stage III-IV BRAF V600E / K-Mutated Melanoma

    This phase I trial studies the side effects and best dose of phenformin hydrochloride when given together with dabrafenib and trametinib in treating patients with stage III-IV BRAF V600E / K-mutated melanoma. Phenformin hydrochloride may work by shrinking the tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving phenformin hydrochloride, dabrafenib, and trametinib may work better at treating melanoma and might prevent the tumor from becoming resistant to treatment.
    Location: 3 locations

  • Dabrafenib, Trametinib and Hydroxychloroquine in Treating Patients with Stage IV Metastatic Melanoma

    This phase I / II trial studies the side effects and best dose of hydroxychloroquine when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IV melanoma that has spread to other places in the body. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sometimes when dabrafenib and trametinib are given, the tumor cells activate a stress response called autophagy. Autophagy provides resistance to dabrafenib and trametinib treatment over time making them less effective. Giving hydroxychloroquine with dabrafenib and trametinib may reduce drug resistance and allow more tumor cells to be killed.
    Location: 3 locations

  • Ceritinib and Trametinib in Treating Patients with ALK Positive Stage IIIB-IV Non-small Cell Lung Cancer

    This phase I / II trial studies the best dose and side effects of ceritinib and trametinib in treating patients with ALK positive stage IIIB-IV non-small cell lung cancer. Ceritinib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    This phase II trial investigates how well azacitidine, venetoclax, and trametinib work in treating patients with acute myeloid leukemia or higher-risk myelodysplastic syndrome that has come back (relapsed) or has not responded to treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and trametinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. The goal of this study is learn if the combination of azacitidine, venetoclax, and trametinib can help to control acute myeloid leukemia or myelodysplastic syndrome.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

    The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
    Location: 2 locations

  • Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB / C / D Melanoma

    This phase II trial studies how well dabrafenib, trametinib, and spartalizumab works in treating patients with BRAF V600E or V600K mutation positive stage IIIB / C / D melanoma, who do not achieve a pathologic complete response after 8 weeks of dabrafenib and trametinib treatment. Patients who achieve a pathologic complete response after 8 weeks of neoadjuvant dabrafenib and trametinib will receive adjuvant dabrafenib and trametinib. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as spartalizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving dabrafenib, trametinib, and spartalizumab may help to control melanoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Dabrafenib, Trametinib, and IMRT in Treating Patients with BRAF Mutated Anaplastic Thyroid Cancer

    This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    This phase Ib trial determines if samples from a patient’s cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Ribociclib, Gemcitabine Hydrochloride, Trametinib, and Sonidegib in Treating Patients with Refractory or Recurrent Brain Cancers

    This phase I trial studies the best dose and side effects of ribociclib, gemcitabine hydrochloride, trametinib, and sonidegib in treating children and young adults with brain cancers that have come back (recurrent) or do not respond to treatment (refractory). Ribociclib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and sonidegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib, gemcitabine hydrochloride, trametinib, and sonidegib may work better at treating brain cancers.
    Location: Saint Jude Children's Research Hospital, Memphis, Tennessee

  • Dabrafenib and / or Trametinib Rollover Study

    This study is to provide access for patients who are receiving treatment with dabrafenib and / or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Pembrolizumab and Trametinib in Treating Patients with Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

    This phase Ib trial studies the side effects of pembrolizumab and trametinib in treating patients with non-small cell lung cancer and KRAS gene mutations that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib may work better in treating patients with non-small cell lung cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Trametinib and Pembrolizumab in Treating Patients with Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

    This phase Ib / II trial studies the side effects and best dose of trametinib when given together with pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer that has come back and spread to other places in the body, cannot be removed by surgery, or spread to nearby tissues or lymph nodes. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving trametinib and pembrolizumab may work better in treating patients with non-small cell lung cancer.
    Location: 2 locations

  • Panitumumab with or without Trametinib in Treating Patients with Stage IV Colorectal Cancer

    This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving panitumumab with or without trametinib may work better in treating patients with stage IV colorectal cancer.
    Location: 2 locations

  • Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants with Refractory and Advanced or Metastatic Solid Tumors with EGFR Mutation / Amplification, HER2 Mutation / Amplification, or HER3 / 4 Mutation or KRAS Mutation

    This phase I trial studies the side effects and best dose of neratinib in combination with everolimus, palbociclib, or trametinib in participants with solid tumors with EGFR mutation / amplification, HER2 mutation / amplification, HER3 / 4 mutation, or KRAS mutation that do not respond to treatment (refractory) and have spread to other parts of the body (advanced or metastatic). Neratinib, palbociclib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving neratinib with everolimus, palbociclib, or trametinib may work better than neratinib alone in treating participants with solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas


1 2 Next >